• No results found

University of Groningen Towards new personalized treatment options for patients with genomically unstable tumors van Gijn, Stephanie Elise

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Towards new personalized treatment options for patients with genomically unstable tumors van Gijn, Stephanie Elise"

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Towards new personalized treatment options for patients with genomically unstable tumors

van Gijn, Stephanie Elise

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

van Gijn, S. E. (2019). Towards new personalized treatment options for patients with genomically unstable tumors. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn Processed on: 6-6-2019 Processed on: 6-6-2019 Processed on: 6-6-2019

Processed on: 6-6-2019 PDF page: 1PDF page: 1PDF page: 1PDF page: 1

Towards new personalized treatment options for patients

with genomically unstable tumors

(3)

531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn Processed on: 6-6-2019 Processed on: 6-6-2019 Processed on: 6-6-2019

Processed on: 6-6-2019 PDF page: 2PDF page: 2PDF page: 2PDF page: 2

The work described in this thesis was conducted at the Department of Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands.

ISBN: 978-94-034-1720-2

ISBN (electronic version): 978-94-034-1719-6

Cover design: Ingrid J. van Gijn-Meijer (www.ingrid-meijer.nl) Lay-out design: Stephanie E. van Gijn & Ingrid J. van Gijn-Meijer Printing: Ipskamp Printing BV, Enschede

Printing of this thesis was supported by: - UMCG Graduate School of Medical Sciences - Stichting Werkgroep Interne Oncologie - University of Groningen

© Copyright 2019, S.E. van Gijn

All rights reserved. No part of this thesis may be reproduced, stored or transmitted in any form without permission by the author.

(4)

531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn Processed on: 6-6-2019 Processed on: 6-6-2019 Processed on: 6-6-2019

Processed on: 6-6-2019 PDF page: 3PDF page: 3PDF page: 3PDF page: 3

Towards new personalized

treatment options for patients with

genomically unstable tumors

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 10 juli 2019 om 09.00 uur

door

Stephanie Elise van Gijn

geboren op 13 januari 1991 te 's-Gravenhage

(5)

531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn Processed on: 6-6-2019 Processed on: 6-6-2019 Processed on: 6-6-2019

Processed on: 6-6-2019 PDF page: 4PDF page: 4PDF page: 4PDF page: 4

Promotor

Prof. dr. M.A.T.M. van Vugt Copromotor Dr. R.S.N. Fehrmann Beoordelingscommissie Prof. dr. R. de Bree Prof. dr. W. Helfrich Prof. dr. F. Foijer Paranimfen Elly L. van der Veen Esméé Joosten

(6)

531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn Processed on: 6-6-2019 Processed on: 6-6-2019 Processed on: 6-6-2019

Processed on: 6-6-2019 PDF page: 5PDF page: 5PDF page: 5PDF page: 5

CONTENT

Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7 Appendix

General introduction & scope of the thesis

TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells

Oncogene, 2018

Elevated protein expression of TPX2 is positively associated with genomic instability in breast carcinomas

Analysis of replication stress and ATR inhibitor sensitivity in head and neck squamous-cell carcinomas

Data-driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma

Oral Oncol, 2018

Summarizing discussion & future perspectives

Dutch summary - Nederlandse samenvatting

Curriculum Vitae List op Publications Dankwoord/Acknowledgements 7 23 49 59 75 89 101 109

(7)

531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn 531746-L-bw-van Gijn Processed on: 6-6-2019 Processed on: 6-6-2019 Processed on: 6-6-2019

Referenties

GERELATEERDE DOCUMENTEN

Aims: To review the literature about the dosing regimen, duration, effects, and side effects of oral, intravenous, intranasal, and subcutaneous routes of administration of

receptor are classic examples of protein-based biomarkers. These protein-based biomarkers are valuable in predicting whether a patient will respond to hormonal therapy or not.

Naast het identificeren van genen of signaleringsroutes waarvan genoom instabiele tumoren afhankelijk zijn geworden voor hun overleving, richten nieuwe kankertherapieën zich ook op

Jullie vriendschap en steun waren onmisbaar tijdens mijn promotieonderzoek en jullie regelmatige gezelschap zorgde altijd voor welkome afleiding.. Dear Christian and Elisabeth,

De positieve associatie tussen TPX2 eiwit expressie en eiwit expressie van pRPA en cytoplasmatische Cycline E, respectievelijk indicator en aandrijver van replicatie stress,

Percutaneous radiofrequency ablation of recurrences of colorectal liver metastases after previous liver surgery is often the only remaining treat- ment modality with potential

[r]

Moreover, treatment duration in the registration studies was limited to a maximum of six months, the next steps (i.e. dose maintenance, down dosing or discontinuation) remain